(Raleigh, N.C.) d-Wise, provider of powerful business solutions for the unique challenges of the Life Sciences & Healthcare industries, will participate in the 2012 CDISC Interchange Europe taking place in Stockholm, Sweden April 16-20. (more…)

(Research Triangle Park, N.C.) NCTechNews, North Carolina’s technology news source, will be blogging live from the BIO International Convention in Washington, D.C. June 27-30 to cover major trends affecting the life sciences community. The BIO International Convention is the largest global event of its kind, attracting the biggest names in biotech and featuring keynotes and sessions from key policymakers, scientists, CEOs, and celebrities, and the world’s largest biotechnology exhibition - the BIO Exhibition. (more…)

(Research Triangle Park, N.C.) Alan Hendricker, Ph.D., Principal Scientist of Structural Chemistry, and Thomas Feinberg, Ph.D., Director of Structural Chemistry, at Catalent Pharma Solutions will have prominent roles at this year’s PQRI workshop entitled “Thresholds and Best Practices for Parenteral and Ophthalmic Drug Products (PODP).” The workshop will be held at the Hyatt Regency in Bethesda, MD on February 22-23, 2011. (more…)

(Research Triangle Park, N.C.) CED, the southeast’s largest entrepreneurial support organization, today announced the life science companies selected to present at its 20th annual Biotech/Life Science Conference. The conference, hosted in partnership with the North Carolina Biotechnology Center and NC BIO, takes place February 21_22, 2011, at the Raleigh Convention Center. This is the first time advance medical technology and biopharma companies are featured at the conference. (more…)

(Research Triangle Park, N.C.) Catalent Pharma Solutions announces the installation of electronic verification applications at its Clinical Supply Services facilities in Philadelphia, PA and Schorndorf, Germany. The addition of these automated process check stations is part of an ongoing investment to reduce customer costs and proactively increase service quality standards to better meet clinical trial needs globally. (more…)

(Burlington, N.C.) Laboratory Corporation of America® Holdings (NYSE: LH) today announced that it has received early termination from the Federal Trade Commission of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, applicable to the acquisition of Genzyme Genetics, a business unit of Genzyme Corp. (NASDAQ: GENZ) by LabCorp. (more…)

(Research Triangle Park, N.C.) Ana T. Menendez, Ph.D., Senior Director of Biotechnology at Catalent Pharma Solutions, will be leading a pre-conference workshop entitled “Fit for Purpose Bioassay Development & Validation” at the 9th Annual Biological Assays Conference in London on November 2, 2010. The conference is designed to improve the development, validation and analysis of biological assays by exposing biopharmaceutical professionals to detailed case studies from fellow peers. (more…)

(Burlington, N.C.) Laboratory Corporation of America Holdings (LabCorp) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and The Bank of New York Mellon, as trustee (Trustee) and the conversion agent. (more…)

(Burlington, N.C.) Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today the nationwide availability of a genetic test to detect the presence of a single polymorphism within the IL-28B gene that has been reported to help predict a person’s response to certain hepatitis C virus (HCV) therapies. (more…)

(Research Triangle Park, N.C.) Catalent Pharma Solutions is pleased to announce that the Optiform™ compound optimization platform, a novel, solid-state and highly-automated analysis platform for salt, crystal-form, and co-crystal screening, developed and refined over the past ten years within GlaxoSmithKline (GSK) will now be broadly available to early development scientists for the first time.  The technology has resulted in faster and more material-efficient development workflows, making it easier to bring new drugs to market faster. The Optiform™ compound optimization platform has been applied to more than 500 compounds, spanning from early stage lead compounds through launched products.  GSK has entered into an agreement with Catalent to utilize the Optiform™ platform to support its internal screening activities. The deal between Catalent and GSK was brokered by SR One, GSK’s corporate venture fund. (more…)

(Research Triangle Park, N.C.) Ana T. Menendez, Ph.D., Senior Director of Biotechnology at Catalent Pharma Solutions, has been invited by the Taiwan Biotech Organization to lead a one-day workshop on GMP Bioassay Validation and GLP Immunogenicity Method Development on July 28, 2010. Dr. Menendez will also be delivering a podium presentation titled “Effective Transfer of Complex Biological Method” at the Key Technology Forum in Protein Drug Development, July 29, 2010. The Forum will focus on upstream process development, downstream process development, analytical and bioassay method development, formulation development and manufacturing, facility construction, and quality assurance and regulatory issues. (more…)

(Research Triangle Park, N.C.) Ana T. Menendez, Ph.D., Senior Director of Biotechnology at Catalent Pharma Solutions, will be leading an interactive pre-conference workshop titled, “Immunogenicity Programs: Not Just Another Box to Check” at the 6th Annual Global Proteins Summit in London, UK. The workshop will be held on June 22 at 12:30pm. The Summit brings together experts from all over the world, presenting the latest developments in protein therapeutics, cell culture expression and immunogenicity. (more…)